Shares of Aurobindo Pharma on Thursday closed over 3 per cent lower after the company's step-down subsidiary received a warning letter from the US health regulator for its unit in New Jersey, US.
The stock, which declined 6.92 per cent to Rs 749.55 during the day on BSE, later closed at Rs 782.45, lower by 2.84 per cent.
On the NSE, it fell 3.37 per cent to settle at Rs 779.
AuroLife Pharma, a wholly-owned step-down subsidiary of the company, has received a warning letter from the United States Food and Drug Administration (USFDA) for its oral solid manufacturing facility situated at Dayton, New Jersey, Aurobindo Pharma said in a BSE filing.
This follows the earlier letter dated June 4, 2020, issuing an OAI (Official Action Indicated) status for this facility.
Aurobindo Pharma said it believes the existing business from this facility will not be impacted.
"The company will be engaging with the regulator and is fully committed in resolving this issue at the earliest," it added.
The drug firm, however, did not provide any details of the contents of the warning letter.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU